Cybin Inc (HELP)

Currency in CAD
9.68
+0.04(+0.41%)
Real-time Data·
Advertisement
HELP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.6810.00
52 wk Range
5.3012.70
Key Statistics
Bid/Ask
9.57 / 9.66
Prev. Close
9.64
Open
9.88
Day's Range
9.68-10
52 wk Range
5.3-12.7
Volume
8.65K
Average Volume (3m)
16.4K
1-Year Change
-6.7437%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HELP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cybin Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
13/02/2026
EPS / Forecast
-1.38 / -0.05
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Cybin (HELP) Income Statement & Profits

Compare HELP to Peers and Sector

Metrics to compare
HELP
Peers
Sector
Relationship
P/E Ratio
−2.9x−2.8x−0.4x
PEG Ratio
0.55−0.040.00
Price/Book
1.8x1.9x2.6x
Price / LTM Sales
-7.0x3.0x
Upside (Analyst Target)
-99.1%51.5%
Fair Value Upside
Unlock15.5%8.8%Unlock

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.

Employees
100
Market
Canada

FAQ

What Is the Cybin (CBOE Canada: HELP) Share Price Today?

The Cybin stock price today is 9.68 CAD.

What Stock Exchange Does Cybin (HELP) Trade On?

Cybin is listed and trades on the CBOE Canada Exchange.

What Is the Ticker (Stock Symbol) for Cybin?

The stock symbol (also called a 'ticker') for Cybin is "HELP."

What Is the Current Cybin Market Capitalisation?

As of today, Cybin (CBOE Canada: HELP) market cap is 602.81M CAD.

What Is Cybin's (HELP) Earnings Per Share (TTM)?

The Cybin EPS is currently -4.25 (Trailing Twelve Months).

Is HELP a Buy or Sell From a Technical Analyst Perspective?

Based on today's Cybin moving averages and other technical indicators, the daily buy/sell signal for HELP stock is Strong Buy.

How Many Times Has Cybin Stock Split?

Cybin has split 2 times. (See the HELP stock split history page for full effective split date and price information.)

How Many Employees Does Cybin Have?

Cybin has 100 employees, based on their latest Companies House report.

What is the current trading status of Cybin (CBOE Canada: HELP)?

As of 13/07/2026, Cybin (HELP) is trading at a share price of 9.68 CAD, with a previous close of 9.64 CAD. The stock has fluctuated within a day range of 9.68 CAD to 10.00 CAD, while its 52-week range spans from 5.30 CAD to 12.70 CAD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.